BioSpace News Archive

Gritstone bio, Inc. announced that the company’s Board of Directors granted seven employees nonqualified stock options to purchase an aggregate of 35,100 shares of its common stock with an exercise price of $2.24, which is equal to the closing price of Gritstone’s common stock on October 11, 2022, the date of the grant.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that four scientific presentations have been accepted at the upcoming American Society of Nephrology (ASN) Kidney Week (November 3-6, 2022) taking place in Orlando, Florida.

Talaris Therapeutics, Inc. today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla.

Decibel Therapeutics today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is designed to provide durable hearing in individuals born with profound congenital hearing loss due to an otoferlin deficiency.

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap’s anti-Dickkopf-1 antibody.

ImmuneID today announced the appointment of Jessica Atkinson as Chief Business Officer, where she will oversee business activities as part of ImmuneID leadership with dual goals of advising on the company’s current direction and exploring and maximizing external collaboration opportunities for its aiSPIRE platform.

Kira Pharmaceuticals, today announced it will present data from its Phase 1 SYNERGY-1 trial of lead candidate KP104 at the American Society of Nephrology (ASN) Kidney Week 2022, occurring November 3-6 in Orlando, FL.

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.

Nutriband Inc. today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24.

M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry-leading data and analytics, today announced the appointment of Kyle Dunn to its executive team as Chief Revenue Officer.